Summary by Moomoo AI
Biodexa Pharmaceuticals PLC, a clinical stage biopharmaceutical company listed on NASDAQ under the ticker BDRX, has announced the posting of its Annual Report and the Notice of its upcoming Annual General Meeting (AGM). The AGM is scheduled to take place at the company's Cardiff office on June 13, 2024, at 12.00 noon BST. Shareholders have been provided with details on proxy voting in the Notice of AGM. The company, which specializes in developing treatments for diseases with unmet medical needs, has also disclosed its total voting rights, amounting to 2,238,225,722 Ordinary Shares, with no shares held in treasury. Biodexa's lead development programs include eRapa for Familial Adenomatous Polyposis and Non Muscle Invasive Bladder Cancer, tolimidone for type 1 diabetes, and MTX110 for rare/orphan brain cancer indications. The company's proprietary drug delivery technologies aim to enhance the bio-delivery and bio-distribution of medicines. The Annual Report and AGM Notice are available on the Biodexa Pharmaceuticals website.